15 results

1 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
KMSID: 1516082516   J Liver Cancer. 2023;23(1):1-120.   Published online 2022 December 9    DOI: http://dx.doi.org/10.17998/jlc.2022.11.07
      
121 How to optimize the treatment strategy for advanced-stage hepatocellular carcinoma with macrovascular invasion
Beom Kyung Kim
KMSID: 1516082523   J Liver Cancer. 2023;23(1):121-123.   Published online 2023 March 24    DOI: http://dx.doi.org/10.17998/jlc.2023.3.10
      
124 Impact of the updated KLCA-NCC criteria for diagnosis of “probable HCC” in liver MRI: comparisons between KLCA v2022 and v2018
Jeong Hee Yoon
KMSID: 1516082525   J Liver Cancer. 2023;23(1):124-126.   Published online 2023 March 21    DOI: http://dx.doi.org/10.17998/jlc.2023.3.7
      
127 Non-alcoholic fatty liver disease-related hepatocellular carcinoma
Darine Daher, Karim Seif El Dahan, Amit G. Singal
KMSID: 1516082512   J Liver Cancer. 2023;23(1):127-142.   Published online 2023 February 9    DOI: http://dx.doi.org/10.17998/jlc.2022.12.30
      
143 Radiologic features of hepatocellular carcinoma related to prognosis
Shin Hye Hwang, Hyungjin Rhee
KMSID: 1516082518   J Liver Cancer. 2023;23(1):143-156.   Published online 2023 March 9    DOI: http://dx.doi.org/10.17998/jlc.2023.02.16
      
157 Diagnostic performance of the 2022 KLCA-NCC criteria for hepatocellular carcinoma on magnetic resonance imaging with extracellular contrast and hepatobiliary agents: comparison with the 2018 KLCA-NCC criteria
Ja Kyung Yoon, Sunyoung Lee, Jeong Ah Hwang, Ji Eun Lee, Seung-seob Kim, Myeong-Jin Kim
KMSID: 1516082515   J Liver Cancer. 2023;23(1):157-165.   Published online 2023 February 23    DOI: http://dx.doi.org/10.17998/jlc.2023.02.07
      
166 Use of doxorubicin-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein invasion: a prospective study
Su Jong Yu, Yun Bin Lee, Eun Ju Cho, Jeong-Hoon Lee, Hyo-Cheol Kim, Jin Wook Chung, Jung-Hwan Yoon, Yoon Jun Kim
KMSID: 1516082513   J Liver Cancer. 2023;23(1):166-176.   Published online 2023 March 3    DOI: http://dx.doi.org/10.17998/jlc.2023.02.08
      
177 Subclassification of advanced-stage hepatocellular carcinoma with macrovascular invasion: combined transarterial chemoembolization and radiotherapy as an alternative first-line treatment
Sujin Jin, Won-Mook Choi, Ju Hyun Shim, Danbi Lee, Kang Mo Kim, Young-Suk Lim, Han Chu Lee, Jinhong Jung, Sang Min Yoon, Jonggi Choi
KMSID: 1516082524   J Liver Cancer. 2023;23(1):177-188.   Published online 2023 March 23    DOI: http://dx.doi.org/10.17998/jlc.2023.03.04
      
189 Current status of ultrasonography in national cancer surveillance program for hepatocellular carcinoma in South Korea: a large-scale multicenter study
Sun Hong Yoo, Soon Sun Kim, Sang Gyune Kim, Jung Hyun Kwon, Han-Ah Lee, Yeon Seok Seo, Young Kul Jung, Hyung Joon Yim, Do Seon Song, Seong Hee Kang, Moon Young Kim, Young-Hwan Ahn, Jieun Han, Young Seok Kim, Young Chang, Soung Won Jeong, Jae Young Jang, Jeong-Ju Yoo
KMSID: 1516082526   J Liver Cancer. 2023;23(1):189-201.   Published online 2023 March 24    DOI: http://dx.doi.org/10.17998/jlc.2023.03.11
      
202 Parenchymal-sparing hepatectomy for multiple bilobar colorectal liver metastases in a Jehovah’s witness: a case report
Shehan Ratnayake, Duminda Subasinghe, Vihara Dassanayake, Sivasuriya Sivaganesh
KMSID: 1516082514   J Liver Cancer. 2023;23(1):202-205.   Published online 2023 February 15    DOI: http://dx.doi.org/10.17998/jlc.2023.01.27
      
206 A case of successful surgical treatment for peritoneal seeding of hepatocellular carcinoma after radiotherapy and atezolizumab plus bevacizumab combination treatment
Yuri Cho, Bo Hyun Kim, Tae Hyun Kim, Young Hwan Koh, Joong-Won Park
KMSID: 1516082517   J Liver Cancer. 2023;23(1):206-212.   Published online 2023 February 24    DOI: http://dx.doi.org/10.17998/jlc.2023.02.09
      
213 A case of nearly complete response in hepatocellular carcinoma with disseminated lung metastasis by combination therapy of nivolumab and ipilimumab after treatment failure of atezolizumab plus bevacizumab
Hyung Jun Kim, Sang Youn Hwang, Jung Woo Im, Ki Jeong Jeon, Wan Jeon
KMSID: 1516082519   J Liver Cancer. 2023;23(1):213-218.   Published online 2023 March 9    DOI: http://dx.doi.org/10.17998/jlc.2023.02.23
      
219 Adult hepatoblastoma: making the challenging distinction from hepatocellular carcinoma
Allison Kaye L. Pagarigan, Paulo Giovanni L. Mendoza
KMSID: 1516082520   J Liver Cancer. 2023;23(1):219-224.   Published online 2023 March 13    DOI: http://dx.doi.org/10.17998/jlc.2023.02.24
      
225 Favorable response of hepatocellular carcinoma with portal vein tumor thrombosis after radiotherapy combined with atezolizumab plus bevacizumab
Yong Tae Kim, Jina Kim, Jinsil Seong
KMSID: 1516082521   J Liver Cancer. 2023;23(1):225-229.   Published online 2023 March 16    DOI: http://dx.doi.org/10.17998/jlc.2023.02.27
      
230 The development of hepatocellular carcinoma during long-term treatment for recurrent non-small cell lung cancer: a case report
Seong Kyun Na, Seong Hee Kang
KMSID: 1516082522   J Liver Cancer. 2023;23(1):230-234.   Published online 2023 March 27    DOI: http://dx.doi.org/10.17998/jlc.2023.03.03
      
Articles from Journal of Liver Cancer are provided here courtesy of The Korean Liver Cancer Association